Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + pemetrexed + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
cyclophosphamide + pemetrexed + 5-fluorouracil is a combination chemotherapy regimen being evaluated by West China Hospital in a Phase 2 clinical trial. This regimen is part of a precision medicine study where treatment selection for locally advanced or metastatic poorly differentiated or anaplastic thyroid cancer is guided by in-vitro drug sensitivity testing using tumor-derived organoids. The combination consists of cyclophosphamide, an alkylating agent that cross-links DNA; pemetrexed, a multi-targeted antifolate that inhibits enzymes involved in purine and pyrimidine synthesis; and 5-fluorouracil, a pyrimidine analog that inhibits thymidylate synthase. This approach aims to improve outcomes in rare and aggressive thyroid cancers that have failed conventional therapies.
- Other names
- Cyclophosphamide+Pemetrexed+5-Fluorouracil
02
Targets
GART (GAR transformylase)DHFR (Dihydrofolate reductase)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on cyclophosphamide + pemetrexed + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + pemetrexed + 5-fluorouracil.